Percentage of S-Phase CD34+ Cells Purified From the BM and the PB of Normal Subjects Receiving rhG-CSF
| Source of Cells . | Pretreatment (%) . | Posttreatment (%) . | ||||
|---|---|---|---|---|---|---|
| . | CFU-GM . | BFU-E . | Total . | CFU-GM . | BFU-E . | Total . |
| PB | ND | ND | ND | 8.2 ± 6.2 | 3.1 ± 4 | 4 ± 5 |
| BM | 39.8 ± 10*† | 17 ± 93-151 | 25.5 ± 123-151 | 52 ± 8*† | 20 ± 123-151 | 34.6 ± 11*† |
| Source of Cells . | Pretreatment (%) . | Posttreatment (%) . | ||||
|---|---|---|---|---|---|---|
| . | CFU-GM . | BFU-E . | Total . | CFU-GM . | BFU-E . | Total . |
| PB | ND | ND | ND | 8.2 ± 6.2 | 3.1 ± 4 | 4 ± 5 |
| BM | 39.8 ± 10*† | 17 ± 93-151 | 25.5 ± 123-151 | 52 ± 8*† | 20 ± 123-151 | 34.6 ± 11*† |
The results are expressed as the mean ± SD of 16 and 10 different experiments from PB and BM samples, respectively. S-phase progenitors were evaluated before and after rhG-CSF treatment by the Ara-C suicide test.
Abbreviation: ND, not done.
Statistically significant (P < .05) compared with pretreatment values.
Statistically significant (P < .05) compared with PB CD34+ cells.